14-day Premium Trial Subscription Try For FreeTry Free
$0.0290
+0.0040 (+15.77%)
At Close: Apr 23, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0200 $0.0500 Tuesday, 23rd Apr 2024 CALA stock ended at $0.0290. This is 15.77% more than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 3.62% from a day low at $0.0290 to a day high of $0.0301.
90 days $0.0200 $0.120
52 weeks $0.0100 $0.500

Historical Calithera Biosciences prices

Date Open High Low Close Volume
Apr 23, 2024 $0.0301 $0.0301 $0.0290 $0.0290 563
Apr 22, 2024 $0.0251 $0.0251 $0.0251 $0.0251 0
Apr 19, 2024 $0.0251 $0.0251 $0.0251 $0.0251 0
Apr 18, 2024 $0.0251 $0.0251 $0.0251 $0.0251 1 075
Apr 17, 2024 $0.0200 $0.0400 $0.0200 $0.0400 5 257
Apr 16, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Apr 15, 2024 $0.0200 $0.0500 $0.0200 $0.0500 1 472
Apr 12, 2024 $0.0200 $0.0200 $0.0200 $0.0200 0
Apr 11, 2024 $0.0200 $0.0200 $0.0200 $0.0200 2 023
Apr 10, 2024 $0.0200 $0.0200 $0.0200 $0.0200 0
Apr 09, 2024 $0.0200 $0.0200 $0.0200 $0.0200 292
Apr 08, 2024 $0.0301 $0.0301 $0.0301 $0.0301 3 548
Apr 05, 2024 $0.0251 $0.0251 $0.0251 $0.0251 101
Apr 04, 2024 $0.0200 $0.0200 $0.0200 $0.0200 0
Apr 03, 2024 $0.0200 $0.0200 $0.0200 $0.0200 867
Apr 02, 2024 $0.0200 $0.0200 $0.0200 $0.0200 0
Apr 01, 2024 $0.0200 $0.0200 $0.0200 $0.0200 561
Mar 28, 2024 $0.0246 $0.0246 $0.0246 $0.0246 163
Mar 27, 2024 $0.0200 $0.0200 $0.0200 $0.0200 1 281
Mar 26, 2024 $0.0200 $0.0200 $0.0200 $0.0200 0
Mar 25, 2024 $0.0200 $0.0200 $0.0200 $0.0200 1 096
Mar 22, 2024 $0.0251 $0.0251 $0.0251 $0.0251 0
Mar 21, 2024 $0.0251 $0.0251 $0.0251 $0.0251 0
Mar 20, 2024 $0.0251 $0.0251 $0.0251 $0.0251 0
Mar 19, 2024 $0.0251 $0.0251 $0.0251 $0.0251 365
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Golden Star

Ticker Date Change Price
LPLA Apr 19 1.64% $262.59
MLI Apr 19 9.87% $52.28
LNG Apr 17 1.33% $156.81
FCN Apr 16 2.58% $207.62
ELV Apr 16 5.12% $506.97
DXC Apr 08 1.39% $20.87
ITCI Apr 05 8.14% $68.44
AKR Apr 05 6.84% $16.53
NSIT Apr 04 0.350% $185.62
VSTS Apr 04 0.638% $18.82
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT